Merck partners with King’s College London to develop painkillers
King’s College London (KCL) has entered a licensing and collaboration agreement with US pharmaceutical company Merck & Co to develop new chronic pain medications.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
28 January 2019 German pharmaceutical company Merck Group has granted US biotech firm Vertex a licence to two DNA-dependent protein kinases inhibitors.
28 January 2019 German pharmaceutical company Merck Group has granted US biotech firm Vertex a licence to two DNA-dependent protein kinases inhibitors.
28 January 2019 German pharmaceutical company Merck Group has granted US biotech firm Vertex a licence to two DNA-dependent protein kinases inhibitors.